|
|
|
| Webinar: From Research to Reality: Overcoming CMC Challenges in Cell & Gene Therapy | Join us on February 20th to learn how to overcome manufacturing and regulatory challenges in cell and gene therapy by developing robust CMC strategies, employing Quality by Design, and implementing phase-appropriate GMP processes. This webinar is ideal for small biopharma companies and institutions seeking to bridge research and commercial development effectively. Click here to learn more. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | The JP Morgan Healthcare conference has never been a venue for directed discussion on outsourcing. That’s not to say such discussions aren’t held. This year, Kurt Nielsen co-hosted an evening devoted to the topic. Nielsen, a veteran outsourcing-industry executive, shares his initial thoughts on the vibe this year. | |
|
|
Building Frameworks To Support Complex Therapy Manufacturing | A conversation with Vadim Klyushnichenko, Calibr-Skaggs Institute for Innovative Medicines | To make its clinical product, CLBR001+SWI019, the Calibr-Skaggs Institute for Innovative Medicines relies on a complex network of contractors from around the globe. |
|
|
One Percent Of A Hundred People's Efforts | By Louis Garguilo, chief editor, Outsourced Pharma | Persephoni BioPartners CEO Hilary Shultz, and newly hired Chief Scientific Officer William Heath – a 34-year veteran of Eli Lilly – explain their biotech-forming business model, dubbed a venture studio, and provide sound advice on working with CDMOs. |
|
|
|
|
|
|
Virus Filtration: Regulations And Mechanisms | Webinar | Cytiva | In this presentation, Dr. Nigel Jackson, Principal Engineer in R&D, offers an in-depth discussion on regulatory guidance and recent updates pertaining to virus filtration. |
|
|
|
|
|
|
Enhancing The Upstream Performance Of AAV Vector Manufacturing | Poster | By A. Apezteguia, J. Keune, and M. Iglesias, Viralgen | Unlock the potential of AAV manufacturing by leveraging data-driven insights and the advanced Pro10™ platform to optimize processes, enhance productivity, and drive innovation in cell and gene therapy. |
|
|
|
|
|
|
|
Take The Next Step In Your mRNA Product Journey | Novartis Contract Manufacturing | Learn how a collaborative approach significantly mitigates risk associated with mRNA product manufacturing and fosters greater agility and speed throughout the development process. |
|
|
There's No Substitute For Deep Analytical Experience | Advanced Medicine Partners | By focusing on precision and quality, we aim to ensure that every therapeutic product meets the highest safety benchmarks, ultimately contributing to more successful treatments for patients in need. |
|
|
What We Do To Help You | Ascend & ABL Inc. | We're your partner in AAV vector design, manufacturability, scale-up, and quality assurance, ensuring product quality from pre-clinical phases to market, and maximizing positive impacts on patients. |
|
|
|
Capacity Update October 2024: Cell & Gene Therapy | IDT Biologika | With over 30 years of GMP manufacturing expertise, we offer dedicated capacity for clinical and commercial gene therapy batches, using advanced AAV platforms and proprietary cell lines. |
|
|
|
OUTSOURCED PHARMA CAPACITY UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
Connect With Outsourced Pharma: |
|
|
|